- Home
- ELVN vs ROOT Comparison
ELVN vs ROOT Comparison
Compare ELVN & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$41.42
Company Overview
Basic Information| Metric | ELVN | ROOT |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 862.0M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ELVN | ROOT |
|---|---|---|
| Price | $41.42 | $55.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $43.40 | ★ $92.40 |
| AVG Volume (30 Days) | ★ 640.9K | 278.9K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.17 | ★ 28.96 |
| EPS | N/A | ★ 2.09 |
| Revenue | N/A | ★ $1,517,100,000.00 |
| Revenue This Year | N/A | $11.73 |
| Revenue Next Year | N/A | $12.80 |
| P/E Ratio | ★ N/A | $27.21 |
| Revenue Growth | N/A | ★ 28.95 |
| 52 Week Low | $14.79 | $40.91 |
| 52 Week High | $48.53 | $162.99 |
Technical Indicators
Market Signals| Indicator | ELVN | ROOT |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 52.94 |
| Support Level | $16.84 | $51.00 |
| Resistance Level | $48.53 | $58.03 |
| Average True Range (ATR) | 2.46 | 3.57 |
| MACD | -0.34 | -0.08 |
| Stochastic Oscillator | 34.79 | 30.14 |
Price Performance
Historical Comparison ELVN
ROOT
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.